{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:24:42Z","timestamp":1778221482594,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20170454"],"award-info":[{"award-number":["BK20170454"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejmech.2018.02.025","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T02:26:24Z","timestamp":1518229584000},"page":"95-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity"],"prefix":"10.1016","volume":"148","author":[{"given":"Baomin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo","family":"Gai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xushi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengqiao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0702-3996","authenticated-orcid":false,"given":"Yinsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.02.025_bib1","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2018.02.025_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","article-title":"NS5A inhibitors in the treatment of hepatitis C","volume":"59","author":"Pawlotsky","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2018.02.025_bib3","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nature04077","article-title":"Unravelling hepatitis C virus replication from genome to function","volume":"436","author":"Lindenbach","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.02.025_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/HMER.S55864","article-title":"Interferon-free combination therapies for the treatment of hepatitis C: current insights","volume":"7","author":"Holmes","year":"2015","journal-title":"Hepatic medicine: evidence and research"},{"key":"10.1016\/j.ejmech.2018.02.025_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2893.2009.01246.x","article-title":"HCV drug discovery aimed at viral eradication","volume":"17","author":"Schinazi","year":"2010","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.ejmech.2018.02.025_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1006\/viro.2000.0662","article-title":"Ser2194 is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A","volume":"278","author":"Katze","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2018.02.025_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.02.025_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1021\/acs.jmedchem.6b00962","article-title":"Selective, and orally bioavailable HCV NS5A inhibitor for treatment of hepatitis C virus:(S)-1-((R)-2-(cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl) pyrrolidine-2-carboxamide","volume":"60","author":"Kang","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.025_bib9","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1021\/jm401507s","article-title":"Discovery and development of simeprevir (TMC435), a HCV NS3\/4A protease inhibitor","volume":"57","author":"Rosenquist","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.025_bib10","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial","volume":"385","author":"H\u00e9zode","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.02.025_bib11","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.02.025_bib12","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r\u2013Ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.02.025_bib13","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1021\/jm401836p","article-title":"Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir","volume":"57","author":"Belema","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.025_bib14","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1021\/jm401499g","article-title":"Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection","volume":"57","author":"Link","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.025_bib15","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"Sulkowski","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.02.025_bib16","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r\u2013Ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.02.025_bib17","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.02.025_bib18","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2018.02.025_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/jvh.12657","article-title":"NS5A inhibitors for the treatment of hepatitis C infection","volume":"24","author":"Gitto","year":"2017","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.ejmech.2018.02.025_bib20","doi-asserted-by":"crossref","first-page":"S780","DOI":"10.1016\/S0168-8278(16)01522-1","article-title":"Real world evaluation of Viekira Pak (ritonavir boosted paritaprevir, ombitasvir and Dasabuvir+\/\u2212 ribavirin) in HCV genotype 1 targeting advanced liver disease (the revital study)","volume":"64","author":"Lubel","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2018.02.025_bib21","series-title":"FDA Approves Technivie for Treatment of Chronic Hepatitis C Genotype 4","author":"U. Food, D. Administration","year":"2015"},{"key":"10.1016\/j.ejmech.2018.02.025_bib22a","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/jm3010114","article-title":"Organosilicon molecules with medicinal applications","volume":"56","author":"Franz","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.025_bib22b","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s11172-015-1005-4","article-title":"Drug design based on the carbon\/silicon switch strategy","volume":"64","author":"Lazareva","year":"2015","journal-title":"Russ. Chem. Bull."},{"key":"10.1016\/j.ejmech.2018.02.025_bib22c","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.bmcl.2016.01.050","article-title":"Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development","volume":"26","author":"Nair","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.02.025_bib23","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1021\/jm00103a005","article-title":"Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl) guanidine, a ligand for. sigma. binding sites","volume":"35","author":"Kimes","year":"1992","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.025_bib24","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1021\/jo8008148","article-title":"Direct and selective arylation of tertiary silanes with rhodium catalyst","volume":"73","author":"Yamanoi","year":"2008","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2018.02.025_bib25","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm401398x","article-title":"Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A","volume":"57","author":"DeGoey","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.025_bib26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In\u00a0vitro and in\u00a0vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.025_bib27","article-title":"Silicon-containing compounds for resisting hepatitis C infection","author":"Zhang","year":"2017","journal-title":"PCT Int. Appl."},{"key":"10.1016\/j.ejmech.2018.02.025_bib28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/hep.25738","article-title":"Efficient replication of primary or culture hepatitis C virus isolates in human liver slices: a relevant ex\u00a0vivo model of liver infection","volume":"56","author":"Lagaye","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2018.02.025_bib29","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1023\/B:PHAM.0000036913.90332.b1","article-title":"Transport characteristics of fexofenadine in the Caco-2 cell model","volume":"21","author":"Petri","year":"2004","journal-title":"Pharmaceut. Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418301533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418301533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T03:39:03Z","timestamp":1565321943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418301533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":31,"alternative-id":["S0223523418301533"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.02.025","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}